Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Clinical trial NCT07291037 · RECRUITING

Trial details

NCT number: NCT07291037
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)

Start date: 2025-10-31
Primary completion: 2029-01-29
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.